Urodynamik pp 17-33 | Cite as

Pharmakologie des Harntraktes

  • C. Hampel
  • J. W. Thüroff


Die Darstellung der Pharmakologie des Harntraktes im Rahmen einer Abhandlung über Urodynamik hat mehrere Gründe. So gelingt die Interpretation urodynamischer Kurven nur mit dem Wissen um physiologische Funktionsabläufe und mögliche Krankheitsursachen. Diese sind nur zum Teil anatomisch, häufig aber auch neurologisch, zellularmetabolisch oder rezeptorvermittelt bedingt. Darüber hinaus hat die Pharmakologie bei urodynamischen Spezialuntersuchungen wie z.B. dem Carbachol-Test bereits Einzug in die Funktionsdiagnostik gehalten. Schließlich ist die Behandlung der drangassoziierten Blasenfunktionsstörung bis heute eine pharmakologische Domäne geblieben und ein Blick auf zukünftige pharmakologische Entwicklungen eröffnet auch für die Stressinkontinenz hoffnungsvolle Perspektiven.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andersson KE (2000a) New roles for muscarinic receptors in the pathophysiology of lower urinary tract symptoms. BJU Int 86(S2): 36–43PubMedGoogle Scholar
  2. 2.
    Andersson KE (2000b) Treatment of overactive bladder: other drug mechanisms. Urology 55 (5A Suppl): 51–57; discussion 59PubMedCrossRefGoogle Scholar
  3. 3.
    Araki I (1994) Inhibitory postsynaptic currents and the effects of GABA on visually identified sacral parasympathetic preganglionic neurons in neonatal rats. J Neurophysiol 72(6): 2903–2910PubMedGoogle Scholar
  4. 4.
    Baldwin JM (1993) The probable arrangement of the helices in G protein-coupled receptors. EMBO J12(4): 1693–1703Google Scholar
  5. 5.
    Chancellor MB, de Groat WC (1999) Intravesical capsaicin and resinife-ratoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 162(1): 3–11PubMedCrossRefGoogle Scholar
  6. 6.
    Clifford GM, Farmer RD (2000) Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 38(1): 2–19PubMedCrossRefGoogle Scholar
  7. 7.
    de Groat WC (1997) A neurologic basis for the overactive bladder. Urology 50 (6A Suppl): 36–52; discussion 53–56PubMedCrossRefGoogle Scholar
  8. 8.
    de Groat WC, Yoshimura N (2001) Pharmacology of the lower urinary tract. Ann Rev Pharmacol Toxicol 41:691–721CrossRefGoogle Scholar
  9. 9.
    Dmochowski RR, Appell RA (2000) Advancements in pharmacologic management of the overactive bladder. Urology 56 (6 Suppl 1): 41–49PubMedCrossRefGoogle Scholar
  10. 10.
    Doren M (1998) Urogenital aging-creation of improved awareness. Am J Obstet Gynecol 178(5): S254–S256PubMedCrossRefGoogle Scholar
  11. 11.
    Downie JW (1999) Pharmacological manipulation of central micturition circuitry. Curr Opin Investig Drugs 1:231–239Google Scholar
  12. 12.
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139(5): 919–922PubMedGoogle Scholar
  13. 13.
    Harriss DR, Marsh KA, Birmingham AT, Hill SJ (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154(3): 1241–1245PubMedCrossRefGoogle Scholar
  14. 14.
    Hegde SS, Choppin A, Bonhaus D et al.(1997) Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120 (8): 1409–1418PubMedCrossRefGoogle Scholar
  15. 15.
    Hills CJ, Winter SA, Balfour JA (1998) Tolterodine. Drugs 55(6): 813–820; discussion 821–822PubMedCrossRefGoogle Scholar
  16. 16.
    Hjalmas K (1999) Desmopressin treatment: current status. Scand J Urol Nephrol Suppl 202:70–72PubMedCrossRefGoogle Scholar
  17. 17.
    Kakizaki H, Yoshiyama M, de Groat WC (1996) Role of NMDA and AMPA glutamatergic transmission in spinal c-fos expression after urinary tract irritation. Am J Physiol 270(5 Pt 2): R990–996PubMedGoogle Scholar
  18. 18.
    Kenny BA, Miller AM, Williamson IJ, JOC, Chalmers DH, Naylor AM (1996) Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 118(4): 871–878PubMedCrossRefGoogle Scholar
  19. 19.
    Kuiper GG, Gustafsson JA (1997) The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410(1): 87–90PubMedCrossRefGoogle Scholar
  20. 20.
    Ozawa H, Chancellor MB, Jung SY, et al. (1999) Effect of intravesical nitric oxide therapy on cyclophosphamide-induced cystitis. J Urol 162(6): 2211–2216PubMedCrossRefGoogle Scholar
  21. 21.
    Parczyk K, Schneider MR (1996) The future of antihormone therapy: innovations based on an established principle. J Cancer Res Clin Oncol 122(7): 383–396PubMedCrossRefGoogle Scholar
  22. 22.
    Pitsikas N (2000) Duloxetine Eli Lilly &Co.Curr Opin Investig Drugs 1(1): 116–121PubMedGoogle Scholar
  23. 23.
    Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3): 413–492PubMedGoogle Scholar
  24. 24.
    Robertson G, Rittig S, Kovacs L, Gaskill MB, Zee P, Nanninga J (1999) Pathophysiology and treatment of enuresis in adults. Scand J Urol Nephrol Suppl 202:36–38; discussion 38–39PubMedCrossRefGoogle Scholar
  25. 25.
    Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB (1996) Botu-linum-A toxin as a treatment of detrusor-sphincterdyssynergia:a prospective study in 24 spinal cord injury patients. J Urol 155(3): 1023–1029PubMedCrossRefGoogle Scholar
  26. 26.
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164(3 Pt 1): 692–697PubMedCrossRefGoogle Scholar
  27. 27.
    Schwinn DA (2001) The role of alpha-1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 88 (Suppl 2): 27–34; discussion 49–50PubMedCrossRefGoogle Scholar
  28. 28.
    Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE (2001) Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 20:105–113PubMedCrossRefGoogle Scholar
  29. 29.
    Somogyi GT, Tanowitz M, Zernova G, de Groat WC (1996) M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J Physiol 496 (Pt 1):245–254PubMedGoogle Scholar
  30. 30.
    Testa R, Guameri L, Poggesi E, et al. (1999) Effect of several 5-hydro-xytryptamine(IA) receptor ligands on the micturition reflex in rats: comparison with WAY 100635. J Pharmacol ExpTher 290(3): 1258–1269Google Scholar
  31. 31.
    Truss MC, Stief CG, Uckert S et al. (2000) Initial clinical experience with the selective phosphodiesterase-l isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18(6):439–443PubMedCrossRefGoogle Scholar
  32. 32.
    Truss MC, Stief CG, Uckert S et al. (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19(5): 344–350PubMedCrossRefGoogle Scholar
  33. 33.
    Wheeler MA, Smith SD, Saito N, Foster HE Jr, Weiss RM (1997) Effect of long-term oral L-arginine on the nitric oxide synthase pathway in the urine from patients with interstitial cystitis. J Urol 158(6):2045–2050PubMedCrossRefGoogle Scholar
  34. 34.
    Yokoyama O, Yoshiyama M, Namiki M, de Groat WC (2000) Role of the forebrain in bladder overactivity following cerebral infarction in the rat. Exp Neurol 163(2):469–476PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • C. Hampel
  • J. W. Thüroff

There are no affiliations available

Personalised recommendations